Los Angeles Business Journal – Featured DxTerity in an innovation special report on November 26, 2018.
http://labusinessjournal.com/news/2018/nov/23/dxterity-stays-nimble/
Robert TerbrueggenCEO and FounderBob Terbrueggen, PhD, has nearly 20 years of experience in the genomics industry. He started his career at Clinical Micro Sensors where he was Director of R&D and oversaw the development of the world’s first bio-electronic DNA detection platform, the e-Sensor. Following the company’s acquisition by Motorola, he became the Director of Research for Motorola Life Sciences. In 2005, he helped start NanoBiomics, which was named best start-up of the year by the Arizona Biotech Association and was subsequently acquired by the Molecular Profiling Institute 9 months after founding. Bob is the inventor of DxTerity’s DxDirect Technology and the principal Investigator on a major US government contract for the development and delivery of the REDI-Dx® High Throughput Biodosimetry Test System. Bob double majored in Chemistry along with Cellular and Molecular Biology at University of Michigan and he received a PhD in Chemistry from the California Institute of Technology (Caltech). He is an inventor on 22 issued US patents and more than 100 associated international patents.
James HealyCFO and SVP Business Development, Co-FounderJim Healy, MS, has led operations, business development and finance for DxTerity® since 2010. Prior to DxTerity, Jim had 25 years of operations and financial leadership in high technology, software and semiconductor companies. He started his career at Hughes and rose to be CFO and Director of Operations at Hughes Communication Products. His leadership in the advanced technology group led to over $250M of new business, including the acquisition of Magnavox Radio division. Jim then cofounded JTA Research, a high-speed semiconductor company, leading to a successful exit to Cadence Design Systems. After acquisition by Cadence and as VP of Business Development, he led new product introduction, M&A and supply chain initiatives expanding the Electric Design Automation Tools and Test Suite. Jim then took the role of CFO and SVP Business Development for Magnify360, an internet advertising start-up, where he raised capital and led business development activities for onsite behavioral targeting for Intuit, Seagate, ServiceMagic and Autobytel. These efforts led to a Top 10 List rating from Frost and Sullivan for marketing automation.
Aviva JacobsVice President, Product DevelopmentAviva Jacobs, PhD, PMP, has over 13 years of experience in the in vitro diagnostics industry with Motorola Life Sciences, which was sold to Osmetech Molecular Diagnostics and GenMark Diagnostics, where she held multiple roles, including Sr. Program Manager, Associate Director of Product Development and Director of Product Technical Services. There, she successfully led projects and cross-functional teams, resulting in the FDA clearance of genetic tests for Warfarin sensitivity, cystic fibrosis, thrombophilia risk and a respiratory viral panel on the XT-8 System. From 2011 to 2015, she served as the Director of Product Development at DxTerity Diagnostics, overseeing the development of a genomic test for radiation exposure, as part of a competitive contract funded by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA). Aviva earned a Bachelor of Science in Biology from the University of Michigan, Ann Arbor and a PhD in Genetics from George Washington University, in conjunction with the National Institutes of Health.
Shelley ArnoldVice President, Quality and RegulatoryShelley Arnold has over 18 years of experience managing quality operations for the commercialization of medical devices into domestic and international markets. Prior to joining DxTerity in 2016, she held management positions at Ansell Healthcare, Sunrise Medical and Nexus Dx (now Samsung), plus key positions in quality, operations and R&D at Nanogen, Accumetrics (now Accriva) and Illumina. She was a key contributor during the early development phases of Illumina’s microarray and genotyping technologies. In that role, she helped to lead project teams through key development activities, including the development and implementation of the first high complexity microarray bead set, establishing a microarray based QC standard and test method for the qualification of BeadArray Readers and established the company’s initial Design Control policies in accordance with FDA QSR and ISO 13485. She also supported development of a LIMS-driven reagent manufacturing process for the microarray platform and SNP genotyping assay. Shelley earned a Bachelor of Science in Chemical Engineering from the University of California, San Diego and is a Certified Quality Engineer and Certified Quality Auditor from the American Society of Quality.
Brett SwansigerCCO - Chief Commercial OfficerBrett has over 20 years of commercial leadership, international business development, and managed care contracting experience within the molecular diagnostics and pharmaceutical industries. Prior to joining DxTerity, Brett held multiple commercial leadership positions at MDxHealth Inc., a multi-national urologic oncology company, including VP of Managed Care and Payer Strategy, SVP International Business Development & European Sales, and SVP of US Sales & Integrated Healthcare Systems. Brett was successful in executing licensing and clinical study contracts with diagnostic and pharmaceutical market leaders as well as getting key integrated healthcare systems like Kaiser Permanente, the Veteran’s Administration, the Department of Defense, and Geisinger to adopt new molecular diagnostic testing pathways. Prior to joining MDxHealth, Brett was Vice President of Managed Care and Asia Market Access for Agendia Inc., and he held multiple commercial leadership positions at Prometheus Laboratories Inc., a Nestlé Health Science company that focuses on personalized medicine for autoimmune disorders.